NEW YORK – Predictive Oncology on Wednesday said it will acquire ZPredicta, a biotech that develops tumor-specific in vitro 3D models to aid drug development.
The acquisition will enable Predictive Oncology to integrate information from ZPredicta's 3D tumor models into its artificial intelligence-based platforms, which analyze multiomics data to inform the development of personalized cancer drugs. The companies didn't disclose the financial terms of their deal.
"The acquisition of ZPredicta adds an established company with clear synergies to Predictive Oncology's team, not to mention a progressive revenue stream," Predictive Oncology CEO J. Melville Engle said in a statement. "But it's not just about what ZPredicta is doing today or the revenue it's generating now — it's about how ZPredicta will complement our larger efforts to accurately predict cancer treatment outcomes and optimal drug formulations to treat specific types of cancer in specific types of patients."
ZPredicta's technology helps pharmaceutical firms determine drug efficacy, evaluate mechanisms of resistance, assess off-target toxicity, and reexamine failed drug candidates. The company launched in 2015 out of startup accelerator Y Combinator.
Predictive Oncology hopes to integrate ZPredicta's tumor models with the capabilities at its various subsidiaries, including Helomics' AI-enabled target discovery platform, TumorGenesis' efforts to grow tumor tissue, and drug formulation testing efforts within Soluble Biotech.
Last year, ZPredicta partnered with Labcorp to develop and commercialize tumor-specific preclinical models based on its 3D cell culture platform.